Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial
Top Cited Papers
- 6 May 2010
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 11 (6), 543-552
- https://doi.org/10.1016/s1470-2045(10)70090-5
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Treating Childhood Acute Lymphoblastic Leukemia without Cranial IrradiationNew England Journal of Medicine, 2009
- Acute mixed lineage leukemia in children: the experience of St Jude Children's Research HospitalBlood, 2009
- Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trialLeukemia, 2009
- Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2008
- Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98Journal of Clinical Oncology, 2006
- Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology GroupBlood, 2006
- Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trialBritish Journal of Haematology, 1998
- The randomization and stratification of patients to clinical trialsJournal of Chronic Diseases, 1974
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958